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Overview of the Thesis 
 
Back ground of the study 
 
Rheumatoid arthritis (RA) is a multi system inflammatory autoimmune disease affecting 
approximately 1% of the general population.[1] Interstitial lung disease (ILD) is one of the 
commonest primary pulmonary manifestations of RA. Rheumatoid arthritis is commoner in 
females, however males are more affected in RA-ILD with a male to female ratio of 2:1 in some 
studies.[3] The onset of RA-ILD typically occurs in the fifth decade of life. 
Age and smoking have been shown to be risk factors for the development of ILD[4] and high 
titres of Rheumatoid factor (RF) and Anti citrullinated antibodies (anti-CCP) are a known risk 
factor for extra-articular manifestations of rheumatoid arthritis, including ILD. Most patients 
with RA-ILD present with symptoms of dyspnoea or cough. 
A restrictive pattern on pulmonary function testing (PFT) is the most common pattern noted on 
spirometry in the majority of patients with RA-ILD, with or without a decrease in diffusing 
capacity of the lung for carbon monoxide (DLCO). 
In RA a variety of patterns are seen on High Resolution Computerised Tomography (HRCT) 
scans, with the most common being usual interstitial pneumonia (UIP), which occurs in 40–62% 
of cases. Non specific interstitial pneumonia (NSIP) is the second most common pattern, 
occurring in approximately11–32% of patients. Other types of patterns seen in RA-ILD include 
organising pneumonia, diffuse alveolar damage (DAD), lymphocytic interstitial pneumonia  
(LIP) and desquamative interstitial pneumonia (DIP). However these are less frequent. 
Currently, there have not been enough randomised controlled trials comparing medications for 
the treatment of RA-ILD. Corticosteroids are still the mainstay of therapy, particularly for cases 
of NSIP, organizing pneumonia or acute flare up of UIP. Cyclophosphamide, azathioprine and 
cyclosporine have been used with varying degrees of success. 
There is a paucity of literature regarding RA-ILD in sub Saharan Africa and its demographic 
distribution as well as relationship to HIV. The aim of this study was to review the demographic 
data, PFT and HRCT scan pattern and treatment outcomes at a quaternary hospital in Durban, 
KwaZulu Natal, South Africa. 
Methods 
 
This was a retrospective electronic chart review. Patients 18 years and older referred to Inkosi 
Albert Luthuli Central Hospital pulmonology clinic diagnosed with RA-ILD between January 
2010 and December 2015 were included in the study. 
Demographic and clinical data, as well as data from special investigations, were captured 
retrospectively from medical records. Demographic data included age, gender and race. Clinical 
data captured were presenting symptoms, pre-existing medical conditions, current functional 
class, date of onset of initial symptoms, and treatment. Special investigations captured included 
results of HRCT, rheumatoid factor level, anti-CCP levels and PFT. 
Ethical approval was granted by the University of KwaZulu-Natal’s Human Research Ethics 
Committee (ref. no. E044/2018). 
Statistical analysis 
 
Demographic data with a normal distribution such as age, gender and race are reported as means 
with standard deviation (SD). Fishers exact test was used for categorical variables. Statistical 
significance was regarded as a p-value <0.05 unless otherwise stated. Continuous variables are 
presented as mean SD. 
Change in symptoms between initial visit and last visit for cough, dyspnoea, forced expiratory 
volume in 1 second (FEV1), or forced vital capacity (FVC), was classified as worse or 
improved/or static. Chi square or Fisher’s exact test was used to compare the change by 
categorical data such as treatment. Initial mean FEV1 and FVC were compared by categories of 
RF and anti CCP using Mann-Whitney tests. Changes in FEV1 and FVC were coded as worse if 
the percentage difference change was 10% or more. Changes by treatment medications were 
analysed using Fisher’s exact test. Pairwise comparisons were then done using azathioprine as a 
reference category using Fisher’s exact tests. Data was analysed using Stata V13 statistical 
software. 
Results. There were 61 subjects, the majority being female (90.2%). Approximately 86.9% were 
50 years and older. The majority of the subjects were Indian 72.1% (n=44), followed by Black 
Africans 23% (n=14) and then Whites 4.9% (n=3). All patients were HIV negative. Patients 
treated with a combination of prednisone and azathioprine had a decline in FVC (p value 0.04). 
There was no improvements or deterioration in patients treated with either drug alone. 
Conclusion.  
This is the first study to our knowledge, in South Africa, to study the demographics and treatment of 
RA-ILD. The majority of patients with RA-ILD at IALCH are of Indian descent, contrary to the 
population demographics of the country which is greater than 80% Black African. Active treatment 
of RA-ILD with prednisone, azathioprine or both combination appears to have had no positive 
impact on symptoms or PFT. However, these results must be interpreted with caution in light of this 
being a retrospective study with its significant shortcomings. 
The management of RA-ILD is still a challenge. The combination of azathioprine and prednisone 
did not arrest disease progression in our study while either agent alone did not improve clinical 
and lung function parameters. Large randomised control studies are needed in Sub-Saharan 
Africa. 
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Rheumatoid arthritis(RA) is a multi system autoimmune disorder that commonly 
affects the joints, causing progressive, symmetric, erosive destruction of joints and 
bone, which is usually associated with auto antibody production (1).  Rheumatoid 
arthritis affects approximately 1% of the general population. The incidence and 
prevalence of rheumatoid arthritis in developing countries is thought to be lower. 
Although joint disease is the main presentation, there are a variety of extra-articular 
manifestations including subcutaneous nodules, vasculitis, inflammatory eye disease 
and lung disease (1, 2). Of these manifestations, lung disease is a major contributor to 
morbidity and mortality. In some patients, respiratory symptoms may precede joint 
symptoms. It is critical to assess systemic and articular signs and symptoms of 
connective tissue disease when evaluating a patient with pulmonary disease of 
unknown aetiology as patients may initially present with respiratory symptoms (1-3). 
 
Pulmonary manifestations of rheumatoid arthritis are protean, with variable patient 
presentations, including parenchymal interstitial lung disease (ILD), pleural 
thickening, and pleural effusion, vasculitis and pulmonary hypertension. These 
changes may reflect chronic immune activation, increased susceptibility to infection 
(often secondary to medications) or direct toxicity from disease modifying or
       biological therapy(1, 4). Prognosis varies depending on the type and severity of 
       involvement.     
 
 
Interstitial lung disease: 
 
Interstitial lung disease (ILD) is the most common pulmonary presentation of 
rheumatoid arthritis lung disease, although the exact prevalence varies depending on 
the population studied and the diagnostic modality used to define the disease. In an 
Australian cohort of rheumatoid arthritis patients with a disease duration <2 years, 
58% of these patients had changes consistent with ILD on either chest radiograph, 
high-resolution computed tomography (HRCT), pulmonary function testing (PFT), 
and bronchoalveolar lavage (BAL) (1, 5, 6). Of these patients, 76% had clinically 
silent disease. A more recent study of 40 patients, also with <2 years of disease, found 
that abnormalities on HRCT scans and/or PFTs were present in 45%, with 10% 
having clinically significant disease. It is currently estimated that approximately 30% 
of patients with RA have subclinical ILD noted on HRCT scans. While the incidence 
of some extra-articular manifestations of rheumatoid arthritis have decreased with 
improvements in therapy, the incidence of ILD has remained fairly stable, if not 
increased. Whether this reflects an increase in detection or is the result of drug- 
induced lung disease with more aggressive use of anti-rheumatic agents is not entirely 
clear (6-8). 
 
Epidemiology and risk factors: 
 
Despite rheumatoid arthritis being more common in females, rheumatoid arthritis 
associated-ILD (RA-ILD) occurs more frequently in males, with a male to female 
ratio 2:1 in some studies. Onset of RA-ILD typically occurs in the fifth decade of life 
(1, 4). The incidence of RA-ILD may increase as newer agents allow better disease 
control and increase life expectancy. Age has consistently been shown to be a risk 
factor for the development of RA-ILD. High levels of rheumatoid factor (RF) and 
anti-cyclic citrullinated peptide (anti-CCP) are a known risk factor for extra-articular 
manifestations of rheumatoid arthritis, including ILD. The exact mechanism for this 




The exact mechanism of pulmonary involvement occurring in RA-ILD is not well 
understood. Patients with rheumatoid arthritis typically have circulating 
autoantibodies, the most common being rheumatoid factor and anti-cyclic citrullinated 
peptide (anti-CCP) (1, 10, 11). These antibodies may be present in the serum for 
several years before clinical disease onset. Both rheumatoid factor and anti-CCP have 
been linked to the development of ILD, particularly when present in high titres (1). 
Cigarette smoking may play a specific role in RA-ILD by promoting citrullination of 
lung proteins, thus leading to the development of anti-CCP antibodies (12). 
A large case–control study from Sweden demonstrated a 21-fold increased risk of 
developing rheumatoid arthritis among those who were anti-CCP positive, smoked 
and had two copies of the shared epitope gene versus non-smokers who did not have 
the shared epitope gene. It is thought that citrullination increases binding of peptides 
to HLA-DRB1 shared epitopes, therefore increasing immunogenicity of these  
proteins (1, 4, 12, 13). 
Ascherman et al reviewed potential biomarkers implicated in RA-ILD (1). To date, 
the following cytokines have been considered as potential biomarkers of ILD: platelet 
derived growth factor isoforms AB and BB, interferon-alpha, and profibrotic cytokine 
transforming growth factor-B1. Elevated levels of these cytokines have been observed 






The clinical presentation of RA-ILD are non-specific. Dyspnea on exertion is the  
most common symptom, and cough, wheezing, and chest pain have also been 
reported. However, dyspnea and physical limitations may not be apparent in the early 
stages of disease (1). 
Chest imaging 
 
In RA-ILD patients chest radiographs frequently show reticular, reticulonodular or 
honeycomb changes in the lung bases. The chest radiograph, however, is insensitive 
as greater than 50% of patients who have a normal plain chest radiograph will have 
abnormalities on their HRCT. Therefore, HRCT has replaced plain chest radiography 
in the initial evaluation of the RA patient with potential lung disease (15, 16, 17). 
 
The incidence of ILD on HRCT depends on the clinical phenotype of the population 
evaluated. A study screening non-smokers without respiratory symptoms found 
evidence of ILD on HRCT in 33%. Early RA (2 years duration) patients have 
evidence of ILD on HRCT in a third of cases, though the extent of disease is mild. In 
both early and longstanding RA, HRCT changes can precede changes in PFTs. In 
looking at patients with clinically suspected ILD (symptoms, impaired lung function, 
or abnormal CXR), 92% have HRCT findings consistent with ILD. The most common 
abnormal findings are ground glass opacities (GGOs) and reticulation, seen in over 
90% of patients, with reticulation seen in 65%–79% of HRCTs, and seen in isolation 
in long-standing disease. GGOs are seen in 27% of patients, rarely seen in isolation, 
and are more common in patients with a shorter duration of disease. Less common 
findings include honeycombing, traction bronchiectasis, nodules, centrilobular 
branching lines, and consolidation. In patients with RA referred to an interstitial lung 
disease centre, patterns of ILD on HRCT include UIP (40%), NSIP (30%), 
bronchiolitis (17%), and organizing pneumonia (8%).75 Other studies have found 
similar percentages of UIP and NSIP. Occasionally, patients will have more than one 
HRCT pattern. HRCT findings are well correlated with underlying histopathology. 
Reticulation and honeycomb change are associated more frequently with pathologic 
UIP. GGOs can be found in both UIP and NSIP but are more pronounced and diffuse 
in the latter. Centrilobular branching is seen with bronchiolitis obliterans and 
consolidation correlates with organizing pneumonia. There are also associations 
between HRCT findings and physiology. The degree of parenchymal involvement in 
RA-ILD is correlated with decreases in FEV1, FVC, and DLCO. Finally, a recent 
study found that survival is linked to HRCT pattern as patients with a “definite UIP” 
pattern had a survival that was significantly worse than those with an indeterminate 
pattern or a pattern suggestive of NSIP (1, 14, 15). 
 
BIOMARKERS FOR RA-ILD 
 
Up to today, the use of RF and anti-CCP as predictive biomarkers for ILD 
development in patients with RA remains controversial. Some evidence indicates that 
there is a clear association between high RF and anti- CCP titer levels and RA-ILD. 
However, other authors have not identified an association between anti-CCP and RA- 
ILD (16). 
To date, there has been a lack of information about serum ferritin in RA-ILD. 
However, a cross-sectional study observed significantly increased matrix 
metalloproteases (MMP)-7 and MMP-1 concentrations in the serum of patients with 




The main histological patterns of ILD have been characterized, including NSIP, usual 
interstitial pneumonia (UIP), DAD, organizing pneumonia (OP), and lymphocytic 
interstitial pneumonia (LIP). The most frequent histological pattern of RA-ILD is 
UIP, followed by NSIP. In terms of severity the UIP pattern in RA-ILD was 
associated with worse survival than the non-UIP pattern. In patients with UIP, the 
mean survival was 3.2 years; in patients with the non-UIP pattern, mean survival time 




RA-ILD patients have an increase in the total cellular population with increases in 
neutrophils, lymphocytes, and eosinophils and a decreased CD4/CD8 ratio on 
bronchoalveolar lavage compared to those without ILD. Abnormal BAL findings can 
also be seen in patients with RA and subclinical ILD and elevated lymphocyte counts 
in these patients may help to distinguish them from those with normal physiology and 
chest radiographs. BAL findings have only a moderate correlation to the lesions found 




Anti-inflammatory and/or immunosuppressive agents are recommended regardless of 
the pattern of fibrosis. This is in contrast to IPF, in which use of immunosuppressive 
therapy has not demonstrated any clinical benefit (17, 18). 
Currently there have been no randomised controlled trials comparing medications for 
the treatment of rheumatoid arthritis lung disease. Corticosteroids are the mainstay of 
therapy, particularly for cases of NSIP or organising pneumonia where they may lead 
to regression of consolidation on imaging and potential clinical improvement (15, 16). 
 
Cyclophosphamide and azathioprine have been used with varying success, and there 
are a few case reports of ILD regression following cyclosporine treatment. More 
recently, several small studies have demonstrated stabilisation and/ or improvement in 
symptoms, imaging and PFTs with use of mycophenolate mofetil (18). A review of 
125 patients with connective tissue disease associated-ILD (18 of which had 
rheumatoid arthritis) found that mycophenolate mofetil was associated with 
improvement in PFTs in patients with non-UIP patterns of ILD, and led to 
stabilisation among those with UIP (11, 14). 
 
Methotrexate, a first-line agent in the treatment of rheumatoid arthritis joint disease, is 
known to be associated with drug induced pneumonitis, but fortunately this is rare. 
However, there is no evidence that this agent leads to progression of ILD. Following 6 
weeks of treatment with high-dose steroids, one group found that treatment with 
methotrexate versus leflunamide or azathoprine was actually associated with an 
improvement in FVC at 6 months among patients with less fibrosis, although there 
was no evidence of differences in other outcomes such as mortality. This suggests that 
methotrexate use may not be associated with poorer outcomes than other disease 
modifying anti-rheumatic drugs (1, 4, 7). 
There is considerable controversy as to whether anti-tumour necrosis factor (TNF) 
agents improve or worsen ILD. Studies evaluating this issue tend to be confounded by 
older age and prior use of methotrexate among participants.  
Adjuvant therapy for RA-ILD includes smoking cessation, management of gastro- 
oesophageal reflux disease, referral to pulmonary rehabilitation, supplemental  
oxygen, and vaccination against influenza and pneumococcal disease (1, 14, 18). 
In the absence of active rheumatoid arthritis, patients with rheumatoid arthritis lung 
disease who fail to respond to therapy should be considered for lung transplant. In 
patients with a UIP pattern, work-up for transplant should be considered early. A 
retrospective review of Canadian patients with advanced lung disease found no 
difference in outcomes between patients with RA-ILD and those with IPF at 1 year 
following lung transplant, suggesting that transplant is a reasonable option for these 




RA-ILD is second only to cardiac disease as a cause of mortality in rheumatoid 
arthritis. Based on a review of mortality data in the USA from 1988–2004, Olson et 
al. calculated that RA-ILD contributed to death in 6.8% of females and 9.8% of males 
with rheumatoid arthritis. Additional risk factors for mortality include advanced age, 
male sex, UIP pattern and extent of fibrosis on imaging or histopathology, and low  
 DLCO(1,10,18).
Overall, RA-ILD has a better prognosis when compared to identical patterns in non- 
connective tissue disease-associated idiopathic interstitial pneumonias. The possible 
exception to this is rheumatoid arthritis associated-UIP, which appears to have poorer 
prognosis compared to other patterns of RA-ILD and, in fact, may have similar 
outcomes to IPF. The mean survival for RA-ILD overall has been estimated at 2.6 
years from time of diagnosis compared to 9.9 years for rheumatoid arthritis patients 
without lung involvement. This probably reflects the predominance of the UIP  
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Background: The prevalence, demographic distribution and treatment outcomes in 
Rheumatoid Arthritis associated interstitial lung disease (RA-ILD) has not been well 
described in Southern Africa. There is very limited data. 
Objective: The aim of the study was to determine the demographic profile of the 
disease as well as treatments used and their outcomes at Inkosi Albert Luthuli Central 
Hospital (IALCH), a tertiary hospital in Durban, South Africa. 
Methods. This was a retrospective electronic chart review of 61 patients who were 
diagnosed with RA-ILD between January 2010 and December 2015 at IALCH 
pulmonology clinic. Demographic and clinical data, symptom presentation, 
pulmonary function testing (PFT), high resolution computerised tomography (HRCT) 
features and treatment modalities were analysed as well as outcome based on 
symptoms, PFT and HRCT. 
Results. There were 61 subjects, the majority being female (90.2%). Approximately 
86.9% were 50 years and older. The majority of the subjects were Indian 72.1% 
(n=44), followed by Black Africans 23% (n=14) and then Whites 4.9% (n=3). All 
patients were HIV negative. Patients treated with a combination of prednisone and 
azathioprine had a decline in FVC (mean 0.41, p value 0.04). There was no 
improvements or deterioration in patients treated with either drug alone. 
Conclusion. The management of RA-ILD is still a challenge. The combination of 
azathioprine and prednisone did not arrest disease progression in our study while 
either agent alone did not improve clinical and lung function parameters. Large 





Rheumatoid arthritis (RA) is a multi system inflammatory autoimmune disease 
affecting approximately 1% of the general population (1). Interstitial lung disease 
(ILD) is one of the commonest primary pulmonary manifestations of RA (2). 
Rheumatoid arthritis is commoner in females, however males are more affected in 
RA-ILD with a male to female ratio of 2:1 in some studies (3). The onset of RA-ILD 
typically occurs in the fifth decade of life (3, 4). 
Age and smoking have been shown to be risk factors for the development of ILD (4) 
and high titres of Rheumatoid factor (RF) and Anti citrullinated antibodies (anti-CCP) 
are a known risk factor for extra-articular manifestations of rheumatoid arthritis, 
including ILD (3-5).  Most patients with RA-ILD present with symptoms of dyspnoea 
or cough (3, 6). 
A restrictive pattern on pulmonary function testing (PFT) is the most common pattern 
noted on spirometry in the majority of patients with RA-ILD, with or without a 
decrease in diffusing capacity of the lung for carbon monoxide (DLCO) (7). An 
obstructive pattern may coexist on PFT and can be seen in patients  manifesting 
airway involvement, such as bronchiolitis obliterans (BO) (3). 
In RA a variety of patterns are seen on High Resolution Computerised Tomography 
(HRCT) scans, with the most common being usual interstitial pneumonia (UIP), 
which occurs in 40–62% of cases. Non specific interstitial pneumonia (NSIP) is the 
second most common pattern, occurring in approximately11–32% of patients. Other 
types of patterns seen in RA-ILD include organising pneumonia, diffuse alveolar 
damage (DAD), lymphocytic interstitial pneumonia (LIP) and desquamative 
interstitial pneumonia (DIP). However these are less frequent (3). 
Once a diagnosis of RA-ILD has been confirmed, treatment is generally directed to 
control the systemic disease with immunosuppressive agents while tailoring therapy 
to the underlying histopathological subtype (8, 9). 
Currently, there have not been enough randomised controlled trials comparing 
medications for the treatment of RA-ILD (8). Corticosteroids are still the mainstay of 
therapy, particularly for cases of NSIP, organizing pneumonia or acute flare up of UIP 
(3, 10). Cyclophosphamide, azathioprine and cyclosporine have been used with 
varying digress of success (3). 
There is a paucity of literature regarding RA-ILD in sub Saharan Africa and its 
demographic distribution as well as relationship to HIV. The aim of this study was to 
review the demographic data, PFT and HRCT scan pattern and treatment outcomes at 
a tertiary hospital in Durban, KwaZulu Natal, South Africa. 
Methods 
 
This was a retrospective electronic chart review. Patients 18 years and older referred 
to Inkosi Albert Luthuli Central Hospital pulmonology clinic diagnosed with RA-ILD 
between January 2010 and December 2015 were included in the study. 
Demographic and clinical data, as well as data from special investigations, were 
captured retrospectively from medical records. Demographic data included age, 
gender and race. Clinical data captured were presenting symptoms, pre-existing 
medical conditions, current functional class, date of onset of initial symptoms, and 
treatment. Special investigations captured included results of HRCT, rheumatoid 
factor level, anti-CCP levels and PFT. 
Ethical approval was granted by the University of KwaZulu Natal’s Human Research 
Ethics Committee (ref. no. E044/2018). 
Statistical analysis 
 
Demographic data with a normal distribution such as age, gender and race are 
reported as means with standard deviation (SD). Fishers exact test was used for 
categorical variables. Statistical significance was regarded as a p-value <0.05 unless 
otherwise stated. Continuous variables are presented as mean SD. 
Change in symptoms between initial visit and last visit for cough, dyspnoea, forced 
expiratory volume in 1 second (FEV1), or forced vital capacity (FVC), was classified 
as worse or improved/ static. Chi square or Fisher’s exact test was used to compare 
the change by categorical data such as treatment. Initial mean FEV1 and FVC were 
compared by categories of RF and anti CCP using Mann-Whitney tests. Changes in 
FEV1 and FVC were coded as worse if the percentage difference change was 10% or 
more. Changes  by  treatment  medications  were  analysed  using  Fisher’s  exact  
test. Pairwise comparisons were then done using azathioprine as a reference category 
using Fisher’s exact tests. Data was analysed using Stata V13 statistical software. 
Results 
Demographics 
There were 61 subjects who met the inclusion criteria with the majority being female 
by far at 90.2%. The majority of patients were above the age of 50 (86.9%). Most of 
the subjects were Indian 72.1% (n=44), followed by Black Africans 23% (n=14) and 
then Whites 4.9% (n=3) (table .1). 
Table 1: Demographic details of the study population. 
 
Age Number % 
40-50 8 13.1% 
50-60 15 24.6% 
60-70 21 34.4% 
70-80 17 27.9% 
Sex 
Male 6 9.8% 
Female 55 90.2% 
Race 
Black African 14 23.0% 
Indian 44 72.1% 





Presenting symptoms and functional status 
Presenting symptoms were recorded at initial visit. The majority of patients had 
exertional dyspnoea as one of their initial symptoms followed by chronic cough. The 
New York Heart Association (NYHA) functional class at enrolment was recorded and 
8 patients (13.1%) were class I disabled, 29 (47.5%) class II, 3 (3.3%) class III and 
none class IV. Twenty two patients (36.1%) had no dyspnoea at initial visit. 
 
Pulmonary function tests 
FEV1 and FVC were recorded in 58 patients with 3 patients having missing data. The 
median FEV1 was 1.54 L with IQR (0.87 – 2.34) . The median FVC was 1.87 L 
(0.75 – 3.02) IQR. 
The majority of patients in our study had a restrictive pattern, 6 patients (9.8%) 
presented with obstructive pattern on PFT and 3 patients had missing data. 
A transfer factor for carbon monoxide was recorded for some patients but the majority 
were not recorded due to lack of data. 
There was a significant difference in percentage change in FVC by weight change, 
Patients who gained weight have greater percentage increase in FVC (p = 0.005, mean 
=21.61, sd=46.28). 
         HRCT analysis showed the following RA-ILD patterns: UIP 36.1% (n=22), followed 
        by NSIP pattern 19.7 % (n=12), BO pattern 9.8% (n=6) and others 34.4% (n=21)  













Figure2 High Resolution Computed Scan Pattern. 
Associations between anti-CCP, RF titres with initial ILD presentation, initial 
lung function test, initial HRCT. 
HRCT Pattern 
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Thirty five patients (57.4%) had a positive anti-CCP titre with a median of 94 IU, 
(30.9-300). Forty one patients (67.2%) had an elevated RF antibody with a median of 
116.5 IU, (46.5-207). There was no association between anti-CCP antibodies or RF 
antibodies with the presenting lung function or HRCT pattern. 
Treatment outcomes 
 
Therapy was categorised into 4 groups: azathioprine alone (n=3, 4.9%), prednisone 
alone (n=10, 16.4%), azathioprine combined with prednisone (n=13, 21.3%), and no 
therapy (n=35, 57.4%). Subjective responses with change in cough and dyspnoea 
were analysed before and after treatment as assessed by first and last visit. HRCT and 
PFT were used as objective responses to treatment before and after therapy. 
The patients were classified as either disease progression or improved or static. There 
was no statistically significant differences in cough, dyspnoea, change in PFT or 
change in HRCT. However patients on prednisone and azathioprine combined had 
significant worsening of the FVC (mean 0.41, IQR (-0.5 to -0.2), p value 0.04). 




RA-ILD is often subtle in onset, slowly progressive and of uncertain response to 
immune modulating agents (11). This study aimed to clarify the current clinical, 
radiographic and pathologic status of RA-ILD and treatment and outcomes of patients 
seen at our tertiary hospital, IALCH, in Durban KwaZulu Natal. 
RA-ILD has been recognised as the most common extra articular complication in RA 
patients. In this retrospective study, we evaluated ILD in RA patients referred to our 
clinic. We found that 86.9% of the patients (n=53) with RA-ILD are between the ages 
of fifty to eighty years. About 13.1 % of the patients (n=8) were less than 50 years of 
age. This is similar to findings in most studies (3, 12). The likely explanation for the 
higher proportion of patients above age of 50 with ILD may be due to long duration of 
disease in the majority of RA patients or late diagnosis. Most patients were females 
(90.2%) as reported in many studies. The study done by Gabriel et al states that RA 
occurs 2–3 times more commonly in women with onset generally in adulthood, 
peaking in the 4th and 5th decade (13).  However male gender has been shown to be a 
risk factor for RA-ILD in a number of studies (12). This gender imbalance has been 
observed across different ethnic populations, as well as in familial studies (12).  In our 
study we found that most of the patients are Indian followed by Black African and 
then White. This finding in is not in line with the demographics of KwaZulu Natal 
and South Africa in which Black Africans comprise more than 80% of the total 
population of both the province and the country. It may be that the Indian race group 
may be more prone to ILD due to RA compared to Black Africans or more prone to 
RA as a disease. Referral patterns in the different race groups may also be a factor. 
Of particular interest are the differential associations observed between 
immunodeficiency secondary to HIV and RA-ILD, which we were unable to establish 
in our cohort. All our patients were HIV negative. Several reports have suggested that 
patients with established rheumatoid arthritis experience clinical improvement after 
the development of immunodeficiency secondary to HIV (14). Tarr et al observed that 
most HIV positive RA patients in their cohort had lower joint counts and composite 
disease activity scores despite stopping immune modulating therapy compared to  
HIV negative controls, supporting the suggestion that HIV infection improves RA 
disease activity (15). There have been no studies thus far in sub-Saharan Africa 
addressing the correlation between HIV and RA-ILD activity. 
The majority of patients in our study had a restrictive pattern on PFT which is similar 
to most studies (3, 6). We identified 6 patients (9.8%) who presented with an 
obstructive pattern. Airflow obstruction may coexist and be seen in patients 
manifesting airway involvement such as bronchiolitis obliterans (3). 
The present study confirms current knowledge from other parts of the world: for 
example Silva et al showed that the predominant pattern of ILD in RA is UIP (14).  In 
our study UIP accounted for more than one-third of patients (36.1%, n=22), followed 
by NSIP pattern (19.7 %, n=12), bronchiolitis obliterans (9.8%, n=6) and others 
(34.4%, n=21). The UIP pattern is independently associated with a poorer prognosis 
and an increase in all-cause mortality (11). 
The differential associations observed between anti-CCP antibodies and rheumatoid 
factor in relation to initial symptoms such as cough, dyspnoea, initial PFT, HRCT 
outcome and HRCT abnormalities are of particular interest. Anti-CCP antibodies are 
highly specific for RA and are associated with poor articular prognosis (16). 
Consistent with most other studies in RA, we have not identified a relationship 
between anti-CCP antibodies or rheumatoid factor and initial symptoms such as cough 
and dyspnoea or initial PFT, nor HRCT patterns. However a study from New Zealand  
demonstrated  an association between anti-CCP antibodies and both physiologic 
abnormalities and bronchial wall thickening on HRCT (16). This may suggest an 
association between the antibody and the interstitial lung disease. 
The management of patients with RA-ILD remains unclear. It is not known whether 
treatment will delay or stop progression of the disease activity. The mainstay of 
treatment in RA-ILD is immune suppressive agents. First line therapy is steroids such 
as prednisone, for prolonged duration especially for non UIP patterns such as NSIP 
and OP. In this retrospective study we found 16.4% of patients had been treated with 
prednisone alone, 4.9% with azathioprine alone, and 21.1% with both prednisone and 
azathioprine. More than half the patients (57.4%) had no specific treatment for the 
RA-ILD. There were no differences in symptoms or PFT outcome between first and 
last visit. However we found that, patients who were on both prednisone and 
azathioprine had a significant decline in FVC. It is very likely that this subgroup of 
patients had both drugs administered because they had the most aggressive disease. It 
is highly unlikely that the associated decline was due to the treatment. It is possible 
that the rate of decline could have been worse if both treatments had not been given. 
The PANTHER study revealed an increased rate of death and hospitalisation in the 
combination therapy group ( prednsione, azathioprine and NAC) compared with 
placebo. More serious adverse events were noted in the combination therapy group 
with no improvement in lung function. Due to these findings, the combination 
regimen arm was stopped and the study terminated prematurely (17). 
 
 
Several studies have raised the possibility that the response to therapy correlates with 
the histological patterns in RA-ILD. RA-ILD with the NSIP pattern has a more 
favourable response to therapy than that with the UIP pattern, resulting in a better 
prognosis. Patients with the OP pattern typically show rapid improvements in 
response to corticosteroid therapy (18). 
 
Limitations of this study 
 
This was a retrospective review of electronic data and only data captured and 
available could be analysed. It was a small sample size at a single centre with missing 
data, which made it very difficult to determine any associations or lack thereof. There 
is the possibility of overestimation as the study was conducted at a tertiary hospital in 
a specialised clinic, which may have resulted in referral bias. There may also have 
been patients with interstitial lung disease at the rheumatology clinic, who may have 





This is the first study to our knowledge, in South Africa, to study the demographics 
and treatment of RA-ILD. The majority of patients with RA-ILD at IALCH are of 
Indian descent, contrary to the population demographics of the country which is 
greater than 80% Black African. None of our patients were HIV infected which may 
attest to previous reports of a protective effect of HIV on RA. 
Active treatment of RA-ILD with prednisone, azathioprine or both combination 
appears to have had no positive impact on symptoms or PFT. However, these results 
must be interpreted with caution in light of this being a retrospective study with its 
significant shortcomings. 
Further prospective multi centre randomised controlled trials are required in this field 
to determine the optimal drug treatment to manage RA-ILD in sub-Saharan Africa as 
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Appendix 1: The final Study Protocol: 
The final Study Protocol 
 
Title of study 
 
Prevalence and outcomes of Rheumatoid Arthritis associated 
Interstitial lung disease at a tertiary level hospital in KwaZulu Natal, 
South Africa: A retrospective 5-year review. 
2.2 Identify the problem that is motivating your research. 
 
Substantiate this claim by anecdotal evidence that derives from your 
practice or clinical experience, specifying the observed factors 
contributing to the problem and the potential outcome. 
Interstitial lung disease (ILD) has been recognized as an important co- 
morbidity in rheumatoid arthritis (RA). We aimed to assess incidence, 
prevalence, risk factors, morbidity and mortality of RA associated ILD. 
2.3 What is the research question or the hypothesis? 
 
Pulmonary involvement is common among patients with rheumatoid 
arthritis and has a variety of manifestations, with ILD, pleural disease and 
pulmonary drug toxicity being the most common. Mechanisms of lung 
injury have been attributed to genetics, environmental exposure and 
medications. Pulmonary disease may precede the development of other 
rheumatoid arthritis manifestations, such as articular involvement, but 
patients with pulmonary disease may also be asymptomatic. Overall, 
morbidity and mortality from rheumatoid arthritis associated-lung disease 
are high. To date, there are no prospective randomised clinical trials for 
RA-ILD and, thus, treatment for RA-ILD is essentially 
immunomodulating agents that are used for rheumatoid arthritis in 
general. Further research is needed to determine specific risk factors and 
appropriate therapy. There is very limited data regarding this disease 
entity in Sub Saharan Africa 
The aim of this study? 
 
To determine the patient profile and treatment outcomes of patients that 
develop Interstitial lung disease associated with RA in the south African 
context. 
The objectives of the study. 
 
a. To determine the incidence and prevalence of patients that develop 
Interstitial lung disease associated with RA. 
b. To describe the demographic profile of the study participants 
c. To examine the specific patterns of ILD on HRCT scan 
d. To examine the management options that patients were placed on for ILD and 
treatment specific outcomes . 
e. To assess the Rheumtoid factor level, CCP level and development of ILD. 
f. To assess PFT parameters before and after treatment 
g. To assess chest radiograph finding of patients with ILD 
h.To determine if there is any increased risk with HIV. 
Background and Literature review 
Besides the joints, the inflammatory process that underlies rheumatoid arthritis (RA) 
also affects other parts of the body, including lungs, skin, eyes, digestive system, heart 
and blood vessels. RA-related lung complications are the most common extra- 
articular manifestations of RA and include pulmonary nodules pleural effusion; 
bronchiectasis and interstitial lung disease (ILD)[1] . 
In fact, it is estimated that 1 in 10 people with rheumatoid arthritis will develop ILD 
over the course of their disease, making it as deadly among people with RA as 
congestive heart failure[2]. 
Interstitial lung disease refers to a group of disorders characterized by inflammation 
and scarring of the lung tissue. In the case of RA-associated ILD, the scarring is 
caused when the over-active immune system attacks the lungs. When the scarring 
builds up over time, breathing becomes difficult, and patients may need lung 
transplants to regain function[3,4], . 
The risk of developing lung disease is eight times higher in people with RA than in 
the general population. However, most people with RA are not affected. Risk factors 
for ILD include: 
Smoking. People with RA who smoke are more likely to develop ILD. 
Higher RA disease activity. High levels of rheumatoid factor (RF) and anti-cyclic 
citrullinated peptides (antiCCP) antibodies – substances that are indicative of more 
active disease – increase the risk for development of ILD,Older age at diagnosis [1]. 
People who are diagnosed with rheumatoid arthritis after age 60 are more likely to 
develop ILD[1]. Male Gender. Men with RA have a two-to-three times higher risk of 
developing ILD than women[2] 
Treatment with methotrexate and other DMARDs. Several DMARDs, including 
methotrexate, leflunomide and azathioprine, as well as biologics, particularly tumor 
necrosis factor (TNF) inhibitors, have been associated with RA-ILD, according to a 
literature review published in the April 2014 issue of Seminars in Arthritis and 
Rheumatism, says the risk of methotrexate-induced lung injury is less than 1 percent 
and is reversible once the drug is stopped[2]. However, methotrexate is not 
recommended for people with existing ILD or RA-ILD by the American College of 
Rheumatology in their 2012 guidelines [3,4]. 
It is challenging to catch ILD early because it doesn’t cause any specific symptoms. 
Once shortness of breath and dry cough develop, the disease has probably already 
progressed [3,4]. 
The diagnostic process includes a comprehensive clinical exam, X-rays and lung 
function tests. If there are risk factors for ILD or abnormal X-ray findings, then 
doctors will likely perform a high resolution CT[5]. 
 
Interstitial lung disease is hard to treat and has a high mortality rate. According to a 
2010 study published in the journal Arthritis & Rheumatism, once ILD was 
diagnosed, the average survival in patients with RA was 2.6 years [3,4]. 
People diagnosed with ILD in its early stages can be helped with medication such as 
corticosteroids and immunosuppressants and put on the waiting list for a lung 
transplant sooner.[5]However, these treatments don’t work for everyone. The best 
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Research design: retrospective observational descriptive study. 
 
 
Study population: Adults (age >18yrs) diagnosed with rheumatoid arthritis with 
interstitial lung disease at Inkosi Albert Luthuli Central Hospital 
6. Study sample: patients (age 12 years) who are diagnosed with rheumatoid arthritis 
with interstitial lung disease during the period between January 2010 and December 
2015. 
Sampling technique: electronic chart review 
Aim for a sample of 50 patients 
Sampling strategy 
The study population will include patients (age 18 years) who diagnosed with 
rheumatoid arthritis with interstitial lung disease in the period between January 2010 
and December 2015. 
Variables 




5. Rheumatoid factor titre 
6. Anti CCP level 
7. Clinical presentation and duration of symptoms. 
8.Radiological findings including CXR and HRCT 
9.Histological findings if done 
10.Pulmonary Function testing 
11.Medications 
12. Outcomes after treatment 
13. HIV status including CD4 count and Viral Load 
14. CRP and ESR level 
Inclusion Criteria: 
All ADULTS (age > 18 years ) diagnosed with rheumatoid arthritis with interstitial 
lung disease at the Department of pulmonology and rheumatology clinics at Inkosi 
Albert Luthuli Central Hospital between 01/01/2010 to 31/12/2015. 
Exclusion criteria: 
-Cases where electronic data sets can not be retrieved. 
-Patients with other connective tissue diseases. 





Data Collection Methods and Tools: 
Research method: data collection sheet. 
Retrospective electronic chart review between January 2010 to December 2015 in the 
Department of pulomonolgy and rheumatology at Inkosi Albert Luthuli Central 
Hospital,Durban,South Africa. 
 
Data analysis techniques: 
Sample Size Determination: 
This project aims to determine the difference between males and females in terms of 
response to rheumatoid arthritis (RA) and interstitial lung disease (ILD). The response 
variables in this study are CT pattern and response to treatment, blood investigation 
and histology. The inclusion criteria is that all participants should be adults (age > 12 
years), diagnosed with RA with ILD at the Department of Pulmonology at Inkosi 
Albert Luthuli Central Hospital between the 1st of January 2010 and 31st of December 
2014. 
The null hypothesis is that there is no statistically significant difference between 
males and females in terms of response to RA and ILD. The following statistical 
parameters were used to arrive the appropriate sample size with a statistical power of 
80%; effect size of 0.99 (magnitude or size of an effect, type 1 (α) error = 0.05 (this is 
the probability of falsely rejecting null hypothesis), type 2 (β) error equal = 0.2 (this is 
the probability of falsely failing to reject null hypothesis). On the base of the above 
statistical parameters, a minimum sample size of 36 was determined. This means that 
36/2 equal to 18 males and 18 females will be included in the study . This condition 




Research data will be primarily be analyzed within a quantitative framework. Data 
will be entered into IBM SPSS, version 24 (Statistical Packages for the Social 
Sciences). A p-value <0.05 will be considered as statistically significant. Continuous 
variables will be expressed as mean ± standard deviation or medians (interquartile 
range) and compared using Student’s t-test or Wilcoxon-Mann-Whitney test as 
appropriate. Proportions and categorical variables will be compared using Pearson’s 
chi-square test or Fisher’s exact test as appropriate. 
 
Study location: 
The study location will include patients (age 12 years) who diagnosed with 




The study population will include patients (age 12 years) who diagnosed with 
rheumatoid arthritis with interstitial lung disease in the period between January 2010 
and December 2015. 
Limitations of the study: 
The study is limited to one center. This may not be truly representative of the general 
population, but as this is the only centre that provides this service for the population 
of Kwazulu-Natal, it is reflective of the state of care for interstial lung disease. 
Due to a retrospective of the study , incomplete data and lack of follow-up may affect 
the findings of this study.. Inconsistencies in capturing of clinical and laboratory data. 
 
Ethical considerations: 
As this is a retrospective study with no patient contact informed consent will not be 
necessary. There will be no direct impact on patient care. No patient identifier will be 
used and subjects will be allocated study numbers. A data sheet these with allocations 
will be kept separating , Confidentiality with all data captured from records will be 
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Preparing an article for anonymous review 
 
To ensure a fair and unbiased review process, all submissions are to include an 
anonymised version of the manuscript. The exceptions to this requirement are 
Correspondence, Book reviews and Obituary submissions. 
 
Submitting a manuscript that needs additional blinding can slow down your review 
process, so please be sure to follow these simple guidelines as much as possible: 
 
 An anonymous version should not contain any author, affiliation or particular 
institutional details that will enable identification. 
 Please remove title page, acknowledgements, contact details, funding grants to a 
named person, and any running headers of author names. 
 Mask self-citations by referring to your own work in third person. 
 
 
General article format/layout 
Submitted manuscripts that are not in the correct format specified in these 
guidelines will be returned to the author(s) for correction prior to being sent for 
review, which will delay publication. 
General: 
 
 Manuscripts must be written in UK English (this includes spelling). 
 The manuscript must be in Microsoft Word document format. Text must be 1.5 line 
spaced, in 12-point Times New Roman font, and contain no unnecessary formatting 
(such as text in boxes). Pages and lines should be numbered consecutively. 
 Please make your article concise, even if it is below the word limit. 
 Qualifications, full affiliation (department, school/faculty, institution, city, country) 
and contact details of ALL authors must be provided in the manuscript and in the 
online submission process. 
 Abbreviations should be spelt out when first used and thereafter used consistently, 
e.g. 'intravenous (IV)' or 'Department of Health (DoH)'. 
 Scientific measurements must be expressed in SI units except: blood pressure 
(mmHg) and haemoglobin (g/dL). 
 Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
 Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' 
but '50%' and '19ºC'. 
 Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not 
B for beta, etc. 
 Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
 Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
 Round brackets (parentheses) should be used, as opposed to square brackets, which 
are reserved for denoting concentrations or insertions in direct quotes. 
 
If you wish material to be in a box, simply indicate this in the text. You may use the 
table format –this is the only exception. Please DO NOT use fill, format lines and so 
on. 
AJTCCM is a medical journal covering all aspects of respiratory health, therefore for 
articles involving genetics, it is the responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and 
proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not 
Tp53. 
** NB: Copyeditors cannot be expected to pick up and correct errors wrt the 
above, although they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, 
e.g. ‘188del11’ can be glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
 
 Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
 HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
 OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
 Bennet et al. Standardized human pedigree nomenclature: Update and assessment of 
the recommendations of the National Society of Genetic Counselors. J Genet Counsel 
2008;17:424-433: standard human pedigree nomenclature. 
 
Preparation notes by article type 
 
Research 
Guideline word limit: 3 000 words (excluding abstract and bibliography) 
Research articles describe the background, methods, results and conclusions of an 
original research study. The article should contain the following sections: 
introduction, methods, results, discussion and conclusion, and should include a 
structured abstract (see below). The introduction should be concise – no more than 
three paragraphs – on the background to the research question, and must include 
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Appendix 4: Data collection tools: 






















HYPERTENSION ,NO (1) 
.YES (2) 
KZ00001883 2 2 1 2 
KZ00002180 2 2 2 1 
KZ00003964 1 2 1 2 
KZ00004029 3 2 2 1 
KZ00006448 3 2 2 1 
KZ00011978 4 2 2 1 
KZ00016316 4 2 2 1 
KZ00016414 4 2 2 1 
KZ00016697 4 2 2 1 
KZ00020015 4 2 3 2 
KZ00021472 3 2 2 2 
KZ00022943 3 2 2 1 
KZ00025140 3 2 1 2 
KZ00027010 4 2 2 1 
KZ00037490 4 2 2 1 
KZ00046318 3 2 1 1 
KZ00046347 4 2 2 1 
KZ00055801 3 2 2 1 
KZ00061935 1 2 2 1 
KZ00062163 2 2 1 2 
KZ00063373 2 2 2 2 
KZ00066491 2 2 2 1 
KZ00107313 2 2 2 2 
KZ00110761 2 2 2 1 
KZ00117745 3 2 1 1 
KZ00119457 1 2 2 1 
KZ00119527 3 2 1 1 
KZ00129659 4 2 2 1 
KZ00135461 3 2 1 1 
KZ00135478 2 2 2 1 
KZ00139434 3 2 2 1 
KZ00140403 3 2 2 1 
KZ00143480 2 1 2 1 
KZ00146419 2 2 2 1 
KZ00149931 3 2 2 1 
KZ00159859 2 2 1 1 
KZ00164215 3 2 2 1 
KZ00172859 1 2 1 1 
KZ00180578 3 1 3 1 
KZ00182714 3 1 3 2 
KZ00185228 1 1 2 1 
KZ00188846 2 2 2 1 
KZ00196156 3 2 2 1 
KZ00205375 2 2 2 1 
KZ00218234 4 2 2 1 


















RA with other connective tissue DYSNEA 






COPD /HPN/DEPRESSION /HYPOTHYRODISM 3 




HPN /AF/GASTRITIS 3 
MIXED CONNECTIVE TISSUE DISEASE /OSTEOPROSIS 2 
SLE / RA overlap/HPN/CKD/CQ MACULOPATHY 1 





Scleroderma / PM/ OSTEOPROSIS 4 
SLE/ RA/ prev myositis/OSTEOPROSIS 1 
SLE 1 
SLE overlap/Hep B/HPN 1 
Asthma/Allergic Rhinitis/HPN/PTB/HYPOTHYRODISM 3 
HPN/OSTEOPROSIS 3 
HPN/T2DM/HEP B/PTB 3 
T2DM/AORTIC SCLEROSIS 3 
HEP B 3 
SLE/Shogrens/T2DM/HPN/CKD 1 
MCTD  / Scleroderma / Polymyositis 2 
OA/IHD/OSTEOPROSIS 3 
Hypothyroid /Hiatus hernia 3 
T2DM/IHD/HPN/OSTEOPROSIS/ALLERGHIC RHINITIS 3 
OA/OSTEOPROSIS 3 
Scleroderma overlap/Lichenoid Photodermatitis 4 
OSA/T2DM/HPN/TKR 3 
OA/HPN/T2DM/DYSLIPIDEMIA 3 
OA/OSTEOPROSIS/IHD /T2DM/HPN/IDA 3 
OA/HPN 3 
KZ00223529 4 2 2 1 
KZ00225855 2 2 1 1 
KZ00233036 4 2 2 1 
KZ00233044 3 1 2 1 
KZ00254374 4 2 1 1 
KZ00261505 4 1 2 1 
KZ00264115 3 2 2 2 
KZ00267210 4 2 2 1 
KZ00267226 4 2 2 1 
KZ00273771 3 2 2 1 
KZ00279659 4 2 2 1 
KZ00281319 1 2 1 1 
KZ00283454 1 2 1 1 
KZ00284490 2 2 2 1 
KZ00290219 1 2 2 2 
 
 OSTEOPROSIS/MDR TB /T2DM/TIA 3  
Diffuse cutaneous systemic sclerosis / MCTD /Myositis 4  
COPD/OSTEOPROSIS/HPN 3  
ASTHMA/HPN /OA/OSTEOPROSIS/pHPN/HYPOTHYRODISM 3  
HPN/COPD 3  
OA 3  
HPN/T2DM/OA/PSORAISIS 3  
HPN 3  
ASYHMA/HPN/T2DM 3  
OA/TKR/THYROID CA 3  
IHD/HPN /T2DM 3  
HPN /T2DM /HYPOTHYRODISM 3  
T2DM/OA/IDA/OSTEOPROSIS/HYPOTHYRODISM 3  
HPN/GOUT/CKD/OA 2  
HPN/SJOGREN/BACKER CYST/RA 2  
COPD/HPN/osteoporosis 3  
SCLERODERMA/T2DM/HPN/PHTN/OSTEOPROSIS/SLE 4  
OA/OSTEOPROSIS/IHD /T2DM/HPN 3  
OA/OS/HYPERTHYRODISM/T2DM/HPN/IHD 3  
OA/HPN/T2DM /HYPOTHYRODISM 3  
ASTHMA/HPN /OA/OSTEOPROSIS/HPN/OSA 2  
MCTD/OA/OS 3  
OS/OA 3  
T2DM/HPN/OS/OA 3  
HPN/PHTN/OA 3  
 
 
COUGH at frist clinic NO(1) .YES (2) 
 
DYSNEA GRADES at last clinic 




1 0 1 
2 2 2 
2 2 2 
1 3 2 
1 0 1 
1 2 1 
1 0 1 
1 3 1 
1 2 1 
1 1 1 
1 0 1 
1 3 1 
1 0 1 
1 0 1 
1 0 1 
1 0 1 
2 2 2 
1 0 1 
2 2 2 
1 3 1 
2 2 1 
2 2 2 
2 2 1 
1 1 1 
2 2 2 
2 2 1 
 
 2 2 2 
1 1 1 
1 0 1 
2 2 2 
1 0 1 
2 2 2 
1 2 1 
2 2 2 
1 0 1 
2 2 2 
1 0 1 
2 2 2 
2 3 2 
2 3 2 
2 2 2 
2 2 2 
1 0 1 
2 2 1 
1 1 2 
2 2 2 
1 0 1 
2 2 2 
1 0 1 
2 0 1 
1 0 1 
1 3 1 
1 0 1 
1 2 1 
1 0 1 
1 0 1 
2 0 1 
2 2 2 
1 0 1 
2 2 2 














NOT DONE  








NOT DONE  
 






NOT DONE  





NOT DONE  
NOT DONE  
60%  
NOT DONE  
NOT DONE  
41%  
39%  
NOT DONE  
38.30%  
NOT DONE  
35%  
NOT DONE  
NOT DONE  
33%  
NOT DONE  
70%  
NOT DONE  




NOT DONE  
NOT DONE  





NOT DONE  
55.50%  
NOT DONE  
49%  
74%  
NOT DONE  
HISTOLOGY TREATMENT AZATHIOPRINE ( 1 ) PR 
NOT DONE  
NOT DONE  
NOT DONE  
NOT DONE  
NOT DONE  
NOT DONE  
NOT DONE  
NOT DONE  
 









































































1.52 1.06 -0.46 -0.30263 -30.26315789 
1.36 1.06 -0.3 -0.22059 -22.05882353 
1.51 1.21 -0.3 -0.19868 -19.86754967 
2.21 1.77 -0.44 -0.1991 -19.90950226 
1.64 1.43 -0.21 -0.12805 -12.80487805 
1.77 1.57 -0.2 -0.11299 -11.29943503 
1.31 1.24 -0.07 -0.05344 -5.34351145 
1.48 1.34 -0.14 -0.09459 -9.459459459 
1.67 1.28 -0.39 -0.23353 -23.35329341 
1.6 1.46 -0.14 -0.0875 -8.75 











1.53 1.71 0.18 0.117647 11.76470588 
1.16 1 -0.16 -0.13793 -13.79310345 
1.12 1.11 -0.01 -0.00893 -0.892857143 
2.03 1.74 -0.29 -0.14286 -14.28571429 
0.98 1.05 0.07 0.071429 7.142857143 
1.31 1.18 -0.13 -0.09924 -9.923664122 
1.75 1.23 -0.52 -0.29714 -29.71428571 
2.34 2.05 -0.29 -0.12393 -12.39316239 
1.71 1.18 -0.53 -0.30994 -30.99415205 
2.23 1.3 -0.93 -0.41704 -41.70403587 
1.28 1.09 -0.19 -0.14844 -14.84375 
1.41 1.4 -0.01 -0.00709 -0.709219858 
1.72 1.98 0.26 0.151163 15.11627907 
1.61 1.56 -0.05 -0.03106 -3.105590062 
1.48 1.09 -0.39 -0.26351 -26.35135135 
1.26 1.43 0.17 0.134921 13.49206349 
1.48 1.04 -0.44 -0.2973 -29.72972973 





















1.81 1.1 -0.71 -0.39227 -39.22651934 
1.21 0.85 -0.36 -0.29752 -29.75206612 
1.42 1.36 -0.06 -0.04225 -4.225352113 
0.94 1.42 0.48 0.510638 51.06382979 
1.21 1.2 -0.01 -0.00826 -0.826446281 
0.78 1.34 0.56 0.717949 71.79487179 
3.31 3.72 0.41 0.123867 12.38670695 
0.87 0.93 0.06 0.068966 6.896551724 
2.09 1.33 -0.76 -0.36364 -36.36363636 
0.65 0.94 0.29 0.446154 44.61538462 
1.92 1.91 -0.01 -0.00521 -0.520833333 
1.26 1.79 0.53 0.420635 42.06349206 
0.86 0.49 -0.37 -0.43023 -43.02325581 
1.59 1.3 -0.29 -0.18239 -18.23899371 
1.47 1.42 -0.05 -0.03401 -3.401360544 
1.28 1.16 -0.12 -0.09375 -9.375 
1.42 1.28 -0.14 -0.09859 -9.85915493 
2.01 1.91 -0.1 -0.04975 -4.975124378 
1.81 2 0.19 0.104972 10.49723757 
2.23 1.67 -0.56 -0.25112 -25.11210762 
1.31 1.2 -0.11 -0.08397 -8.396946565 
1.24 1.13 -0.11 -0.08871 -8.870967742 
1.43 0.88 -0.55 -0.38462 -38.46153846 
1.21 0.98 -0.23 -0.19008 -19.00826446 
1.11 1.41 0.3 0.27027 27.02702703 
1.85 2.21 0.36 0.194595 19.45945946 
1.65 1.65 0 0 0 
2.18 1.91 -0.27 -0.12385 -12.3853211 
2 2.1 0.1 0.05 5 
LUNG FUNCTION TEST OUTCOME Fev1 (1)static ,(2)-DECLINED (3).NOT DONE 
(4).IMPROVED 
    2 
    2 
    2 
    2 
    2 
    2 
    1 
    1 
    2 
    1 
    2 
    3 
    4 
    2 
    1 
    2 
    1 
    1 
    2 
    2 
    2 
    2 
    2 
    1 
    4 
    1 
    2 
    4 
    2 
    1 
    3 
    3 
    2 
    2 
    1 
    4 
    1 
    4 
    4 
    1 
    2 
    4 
    1 
    4 
    2 
    2 
    1 
    1 
    1 
    1 
    4 
    2 
    1 
    1 
    2 
    2 
    4 
    4 
    1 
    2 

























































































































































1.17 1.21 0.04 0.034188 3.41880342 
1.42 1.51 0.09 0.06338 6.33802817 








































































1.28 1.5 0.22 0.171875 17.1875 
1.86 1.74 -0.12 -0.06452 -6.4516129 



















































1.23 2.02 0.79 0.642276 64.2276423 
1.23 1.23 0 0 0 
0.75 1.67 0.92 1.226667 122.666667 
3.42 4.09 0.67 0.195906 19.5906433 
1.43 1.59 0.16 0.111888 11.1888112 











2.2 2.36 0.16 0.072727 7.27272727 



















































2.47 2.47 0 0 0 











1.61 1.55 -0.06 -0.03727 - 































1.68 2.02 0.34 0.202381 20.2380952 
1.97 2.6 0.63 0.319797 31.9796954 











2.44 2.41 -0.03 -0.0123 -1.2295082 
LUNG FUNCTION TEST OUTCOME FVC 1:(1)STATIC. (2)DECLINED (3).NOT DONE (4).IMPROVED 
    2 
    2 
    2 
    2 
    2 
    1 
    1 
    1 
    2 
    1 
    1 
    3 
    2 
    2 
    1 
    2 
    1 
    1 
    1 
    1 
    2 
    2 
    2 
    1 
    4 
    1 
    1 
    4 
    1 
    1 
    3 
    3 
    2 
    2 
    1 
    4 
    1 
    4 
    4 
    4 
    2 
  2 
  1 
  4 
  2 
  2 
  1 
  1 
  1 
  1 
  4 
  2 
  1 
  1 
  2 
  1 
  4 
  4 
  1 
  1 





DIFFUSION CAPACITY OF CARBON MONOXIDE 
(DLCO) 
81% NOT DONE 40% 
75% 580M 50% 
81% 400M 30% 
71% 380M 45% 
76% 470M 50% 
79% 360M 40% 
73% 480M 60% 
85% NOT DONE NOT DONE 
69% NOT DONE NOT DONE 
82% 380M 30% 
79% 360M 35% 
NOT DONE NOT DONE 30% 
86% 600M NOT DONE 
82% 480M 50% 
63% 380M 55% 
82% 390M 45% 
87% NOT DONE NOT DONE 
78% NOT DONE NOT DONE 
66% 368M 40% 
85% 320M 30% 
64% 390M 45% 
80% 400M 41% 
73% 380M 30% 
82% NOT DONE NOT DONE 
83%  NOT DONE NOT DONE 
89% 600M 40% 
60% 300M 30% 
95% NOT DONE NOT DONE 
60% NOT DONE NOT DONE 
75% 300M 60% 
NOT DONE NOT DONE NOT DONE 
NOT DONE NOT DONE NOT DONE 
  74% 300M  41% 
 80% 360M  39% 
 69% NOT DONE NOT DONE 
 70% NOT DONE  38.30% 
 98% NOT DONE NOT DONE 
 80% 400M  35% 
 91% NOT DONE NOT DONE 
 58% NOT DONE NOT DONE 
 68% NOT DONE  33% 
 132% NOT DONE NOT DONE 
 81% 390M  70% 
 72% NOT DONE NOT DONE 
 61% NOT DONE NOT DONE 
 88% NOT DONE  33% 
 83% 285M  44% 
 85% 320M 33,5%  
 73% NOT DONE NOT DONE 
 77% NOT DONE NOT DONE 
 77% NOT DONE NOT DONE 
 67% 228m  25% 
 77% NOT DONE  36% 
 76% 320M  40% 
 75% 175M  28.50% 
 61% NOT DONE NOT DONE 
 70% NOT DONE  55.50% 
 85% NOT DONE NOT DONE 
 90% 460M  49% 
 86% 600M  74% 
 87% 331M NOT DONE 
RF 
LEVEL 
RF(1).POSITIVE (2).NEGATIVE 3.NOT 
DONE 
 
ANTI CCP LEVEL(1).POSITIVE (2).NEGATIVE 3 NOT 
200  1 
20  1 
0.1  2 
147  1 

















16  1 














180  1 
0  2 































































HIV N NEGATIVE P POSITIVE 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
n 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
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